Novo Nordisk

Vivani Medical is developing an implant containing semaglutide, the active ingredient in Novo Nordisk's obesity treatment Wegovy and diabetes drug Ozempic, as a new approach to help patients maintain weight loss.

The article discusses how drugmakers like Eli Lilly and Novo Nordisk promote classifying obesity as a chronic disease to justify long-term medical treatments. They cite the World Health Organization's recognition of obesity as a disease, aiming to frame it as a medical problem requiring pharmaceutical solutions.

Sales of fat-loss drugs in India have slowed after an initial surge driven by generic versions of semaglutide-based medications. Semaglutide is the active ingredient in Novo Nordisk’s Ozempic and Wegovy.

Novo Nordisk is launching its new weight loss pill in the United Arab Emirates as part of a global rollout. The company aims to regain market position against rival Eli Lilly in the weight loss drug sector.

A U.S. judge blocked Colorado from capping the price of Amgen's Enbrel, citing potential harm to the company, while a new Medicare program will offer obesity drugs at $50/month. Novo Nordisk and Eli Lilly's weight-loss treatments will be included in the trial.

Shantha Biologics will provide cartridge fill-finish services for Novo Nordisk. The partnership involves manufacturing and pharmaceutical services.

Medicare will start covering weight-loss drugs via a temporary pilot program on July 1, allowing millions of enrollees access to medications like Wegovy and Zepbound at significantly reduced costs under a deal with Eli Lilly and Novo Nordisk. The program aims to address obesity as a treatable disease, offering seniors like Mary and Jeff Abrahamson affordable options that improve health outcomes.

Medicare is offering select GLP-1 weight loss drugs for $50/month through a temporary trial until 2027, with eligibility based on BMI and specific health conditions. Covered medications include Eli Lilly's Foundayo and Zepbound, and Novo Nordisk's Wegovy, but exclusions apply for those with diabetes or sleep apnea.

Northwestern State University's proposed law school faces stalled approval despite President Jimmy Genovese's efforts, while Medicare begins covering GLP-1 weight-loss drugs for obesity treatment. The Trump administration plans to allocate $500 million to support smaller meatpackers amid high beef prices.

Medicare will cover GLP-1 weight-loss treatments through a temporary pilot program starting July 1, allowing eligible participants to pay a $50 monthly co-pay. The program includes Eli Lilly’s Zepbound and Foundayo and Novo Nordisk’s Wegovy, with coverage ending by 2027 due to federal law restrictions. Eligibility requires a BMI of 35 or higher (or 30 with specific health conditions), and prior authorization is needed.

Medicare will begin covering obesity drugs for the first time, potentially expanding access for seniors and creating new patient opportunities for Novo Nordisk and Eli Lilly.

The Trump administration's deal with Eli Lilly and Novo Nordisk on GLP-1 drugs aimed for lower Medicare/Medicaid prices in exchange for higher sales volume, but companies secured higher sales without lowering prices in some cases. The $245 monthly price was contingent on private insurers covering the drugs with a $50 copay, a condition not publicly disclosed by the administration.

European companies like ASML, Novo Nordisk, and Mistral have achieved global leadership in technology and pharmaceuticals despite structural challenges such as limited venture capital and lower capital investment. The article highlights recent growth in European venture capital and private equity, emphasizing the need to scale these successes through public-private partnerships and a unified single market.

Medicare will cover weight-loss drugs for the first time starting July 1 through a temporary pilot program called Medicare GLP-1 Bridge. The program aims to reduce costs for medications like Zepbound and Wegovy, which are expensive without insurance, providing financial relief for seniors like Mary and Jeff Abrahamson who previously relied on compounded versions of tirzepatide.

Clive Meanwell, chairman of Population Health Partners, leveraged a competitive bidding war between Pfizer and Novo Nordisk for obesity startup Metsera, which reached a $10 billion offer. He now focuses on AI-driven solutions to address large-scale health challenges through innovative technologies and business models.

New GLP-1 weight-loss pills from Novo Nordisk and Eli Lilly are expected to increase consumer demand, but employer-sponsored health insurance plans may not cover the costs of these medications.

Brazil's Hypera filed to launch Semavy, a semaglutide pen targeting the same drug class as Novo Nordisk's Ozempic. The Brazilian semaglutide market generates at least R$5bn ($960m) annually, and the drug's patent expired in March 2026. Rival EMS already secured approval for a competing product.

Pharmaceutical companies are developing drugs to preserve muscle mass during weight loss, addressing an issue with existing GLP-1 drugs like Ozempic. Candidates such as bimagrumab, SPX-001, and CagriSema aim to reduce fat while retaining lean mass, with Cambrian Biotech testing a drug that mimics exercise to boost metabolism.

GLP-1 weight loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound are popular, prompting competitors like Pfizer and Amgen to develop similar products. The article discusses market competition and strategies by Novo Nordisk and Eli Lilly to maintain dominance in the weight loss drug sector.

Hackers claim to have stolen over a terabyte of sensitive data from Novo Nordisk, a pharmaceutical company, after they refused to pay a $25 million ransom. The stolen data includes drug and AI secrets.

A cyber extortion group claimed to have stolen over a terabyte of data from Novo Nordisk, including proprietary information and AI model data, and demanded $25 million. The U.S. Food and Drug Administration reversed its opposition to an experimental Huntington’s disease treatment, allowing UniQure to pursue marketing approval.

Medicare will cover weight loss drugs for adults 65 and older starting next month via a temporary government program. Novo Nordisk plans to seek Chinese regulatory approval for its Wegovy weight loss pill soon amid competition from generic drugmakers.

iRhythm, a California-based cardiac monitoring company, confirmed a data breach where cybercriminals stole patient health information and proprietary data. Attackers demanded payment to avoid public disclosure, though the breach did not affect clinical systems or patient care. The incident was attributed to social engineering, and the company has cyber insurance to cover potential losses.

A study by the National Bureau of Economic Research found that middle-aged adults using GLP-1 drugs for obesity could save $192,735 in lifetime medical costs on average, with higher savings ($220,000) for those without college degrees. The study attributes these savings to GLP-1s' direct impact on appetite and metabolism, which benefits individuals with limited time for diet/exercise regimens.

Drugmakers are competing to enter the obesity drug market currently dominated by Novo Nordisk and Eli Lilly. The article highlights the pharmaceutical industry's interest in this lucrative sector.

Danish pharmaceutical giant Novo Nordisk disclosed a data breach affecting patient information from some clinical trials. The breach impacts data related to clinical trials conducted by the company.

The weight-loss drug Wegovy will be available in pill form in the UK for the first time. Novo Nordisk, the drug's manufacturer, states that a daily tablet may offer greater convenience for some patients compared to weekly injections.

Some employers plan to drop coverage of GLP-1 weight loss drugs in 2027 as usage rises, despite lower prices for medications like Novo Nordisk’s Zepbound and Eli Lilly’s Foundayo. Rapid adoption of GLP-1 drugs in the U.K. has reduced annual grocery spending by $1 billion, with 6.3% of households now including at least one user.

Novo Nordisk and Eli Lilly are competing in the GLP-1 pill market as they prepare to target seniors with Medicare coverage. The two companies have extended their rivalry to this new area of pharmaceutical development.

Pfizer's monthly injectable weight loss drug berobenatide showed side effects similar to Novo Nordisk's Wegovy in a mid-stage trial, with comparable rates of nausea and vomiting.

Novo Nordisk's Wegovy weight loss pill has reached 3 million U.S. prescriptions, with over 80% of new prescriptions issued to patients who had never previously taken a GLP-1 drug.

Novo Nordisk CEO Mike Doustdar highlights the potential of the company's obesity drugs, such as Ozempic and Wegovy, to impact longevity and other healthcare areas beyond weight loss. The drugs' active ingredient, semaglutide, shows possible benefits for organ protection and slowing aging-related processes, even before significant weight loss. Investors are urging the company to diversify as competitors like Eli Lilly expand into broader markets.

Boehringer Ingelheim's obesity drug survodutide showed 13% weight loss in a Phase 3 trial, lower than Novo Nordisk's Wegovy and Eli Lilly's Zepbound. While the drug reduced liver fat by 63%, it appears less efficacious and tolerable compared to existing treatments.

President Donald Trump announced the expansion of the TrumpRx.gov prescription drug discount program, adding 160 medications to bring the total to over 800. The program uses 'most-favored-nation' pricing agreements with pharmaceutical companies, including Eli Lilly and Novo Nordisk, to offer discounted drugs to consumers.

President Donald Trump announced the expansion of TrumpRx.gov, adding 160 prescription drugs to bring the total to over 800 discounted medications. The program uses 'most-favored-nation' pricing agreements with pharmaceutical companies to offer lower prices to eligible consumers.

Cigna will stop covering GLP-1 weight loss drugs like Wegovy and Zepbound in its employee health plan starting July 1, directing users to cash-pay options. A study suggests long-term use of GLP-1 drugs could reduce knee replacement risk by up to 5% over eight years. Prices for these drugs are declining in 2026 with new oral versions.

Novo Nordisk is rolling out the Wegovy pill in the UAE, its first market outside the U.S. The company's global launch approach is guided by patient demand and the strength of healthcare and telehealth infrastructure.

Telehealth companies offering GLP-1 weight loss medications face scrutiny after patients report severe adverse effects and dosage errors. Karleigh McClain was hospitalized following an overdose linked to a semaglutide prescription from a telehealth provider, highlighting concerns about medication safety and inadequate oversight in online healthcare services.

Medicare will cover Wegovy and Zepbound for weight loss starting July 2024 at $50/month for beneficiaries, but has not disclosed the cost to taxpayers. The temporary 'GLP-1 Bridge' program, running until December 2027, bypasses federal law and shifts most costs to taxpayers. The Trump administration initially planned coverage through Medicare Advantage plans, but insurers opposed due to high costs.

France becomes the first EU country to reimburse anti-obesity drugs like Wegovy and Mounjaro for severely obese patients starting mid-June. The policy, announced by Health Minister Stephanie Rist, is estimated to cost the state €100 million annually.